Effect of spleen aminopeptide on asthmatic children with recurrent respiratory infection

Objective To investigate the efficacy and safety of spleen aminopeptide oral lyophilized powder on child,ren with bronchial asthma complicated by recurrent respiratory infection (RRI) in whom the therapy of inhaled corticosteroids (ICS) were inefficacy. Methods A double, blind randomized trial was conducted from Aug. 2004 to Aug. 2005. Fifty, six asthmatic children with RRI were randomly divided into two groups,one receiving spleen aminopeptide and the other receiving placebo,respectively. The severity of RRI and asthma,blood lymphocyte subgroup ratio,and the adverse effects were investigated in two groups. Results There was remarkable clinical responses to spleen aminopeptide with the significant reductions in the frequency of both infection and asthma episodes,the days of fever,cough and wheeze,and the days of antibiotic therapy ( P 0.05 for all). The elevation of T lymphocytes CD3,CD4,CD8 lasted for 6 months after the treatment of spleen aminopeptide comparing to those before treatment ( P 0.01 for all),while having no significant changes in placebo group ( P 0.05 for all). Conclusions It will be feasible that spleen aminopeptide can be used to treat children with bronchial asthma complicated by RRI with a beneficial effect.